コンテンツへスキップ
Merck

RMHMAG-84K

Millipore

MILLIPLEX® Rat Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay

The analytes available for this multiplex kit are: Amylin (Active), C-Peptide 2, Ghrelin (Active), GIP (Total), GLP-1 (Active), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNF-α.

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12161503
eCl@ss:
32161000
NACRES:
NA.84

To order a Milliplex® kit, please search for your analyte of interest.

品質水準

交差性

rat

メーカー/製品名

Milliplex®

assay range

accuracy: 103%
(Amylin (Active))

accuracy: 96%
(GLP-1 (Active))

accuracy: 96%
(IL-6)

accuracy: 96%
(MCP-1)

accuracy: 98%
(TNFα)

accuracy: 99%
(C-Peptide 2)

accuracy: 99%
(Insulin)

sensitivity: 1-62 pg/mL
standard curve range: 14-10,000 pg/mL
(Glucagon & TNFα)

standard curve range: 2.7-2,000 pg/mL
(GIP (Total))

standard curve range: 41-30,000 pg/mL
(Amylin (Active) & GLP-1 (Active))

standard curve range: 69-50,000 pg/mL
(C-Peptide 2, IL-6, Insulin, Leptin & MCP-1)

standard curve range: 7-5,000 pg/mL
(Ghrelin (Active), PP & PYY (Total))

テクニック

multiplexing: suitable

検出方法

fluorometric (Luminex xMAP)

輸送温度

wet ice

詳細

Metabolic syndrome is a cluster of conditions, including increased blood pressure, elevated insulin levels, abnormal cholesterol levels and excess body fat around the waist. Key features of metabolic syndrome include insulin resistance, glucose intolerance, hypertension, dyslipidemia, and central obesity.

MILLIPLEX® Rat Metabolic Panel is a 13-plex kit to be used for the simultaneous quantification of any or all of the following analytes in tissue/cell lysate and culture supernatant samples and serum or plasma samples: Amylin (active), C-peptide 2, Active Ghrelin, GIP, GLP-1, Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, and TNFα. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Metabolism

特異性

Cross Reactivty
No significant cross-reactivity with other hormones tested.

アプリケーション

  • Analytes: Amylin (Active), C-Peptide 2, Ghrelin (Active), GIP (Total), GLP-1 (Active), Glucagon, IL-6, Insulin, Leptin, MCP-1 (CCL2), Pancreatic Polypeptide (PP), PYY (Total), TNFα
  • Recommended Sample Type: Rat serum, plasma, cell/tissue culture supernatants and lysates.
  • NOTE: For specific analytes protease inhibitors should be added upon blood collection: DPPIV for GLP-1 (Active); Protease Inhibitor Cocktail for Amylin (Active); Aprotinin for Glucagon; Serine Protease Inhibitor for Ghrelin (Active)
  • Recommended Sample Dilution: 25 μL per well of neat serum or plasma; cell/tissue culture samples may require dilution in an appropriate control medium.
  • Assay Run Time: Overnight (18-20 hours) at 2-8°C
  • Research Category: Metabolism
  • Research Subcategory: Metabolic Disorders, Obesity, Endocrine

特徴および利点

Design your multiplex kit by choosing available analytes within this panel.

法的情報

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

ピクトグラム

Skull and crossbonesEnvironment

シグナルワード

Danger

危険有害性情報

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Skin Sens. 1

補足的ハザード

保管分類コード

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

毒物及び劇物取締法

キットコンポーネントの情報を参照してください

PRTR

キットコンポーネントの情報を参照してください

消防法

キットコンポーネントの情報を参照してください

労働安全衛生法名称等を表示すべき危険物及び有害物

キットコンポーネントの情報を参照してください

労働安全衛生法名称等を通知すべき危険物及び有害物

キットコンポーネントの情報を参照してください

カルタヘナ法

キットコンポーネントの情報を参照してください

Jan Code

キットコンポーネントの情報を参照してください


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Carolina Soares Moura et al.
Food & nutrition research, 61(1), 1290740-1290740 (2017-03-23)
Background: Several physiologically beneficial effects of consuming a whey protein hydrolysate (WPH) have been attributed to the greater availability of bioactive peptides. Aims: The aim was to investigate the effect of four branched-chain amino acid- (BCAA-)containing dipeptides, present in WPH
Atanu Pal et al.
Diabetes, 64(6), 1941-1950 (2015-01-13)
The antidiabetes effects of Roux-en-Y gastric bypass (RYGB) are well-known, but the underlying mechanisms remain unclear. Isolating the proximal small intestine, and in particular its luminal glucose sensors, from the nutrient stream has been proposed as a critical change, but
Starr Villavasso et al.
Nutrients, 11(11) (2019-11-14)
We have previously shown that 6 weeks of intermittent high-fat diet (Int-HFD) pre-exposure significantly reduced alcohol drinking in rats, providing preliminary evidence of the effectiveness of a dietary intervention in reducing alcohol intake. However, the functional framework and underlying neurobiological
Jean-Baptiste Cavin et al.
Gastroenterology, 150(2), 454-464 (2015-10-21)
Bariatric procedures, such as Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG), are the most effective approaches to resolve type 2 diabetes in obese individuals. Alimentary glucose absorption and intestinal disposal of blood glucose have not been directly compared
Alexander A Moghadam et al.
Experimental biology and medicine (Maywood, N.J.), 242(18), 1786-1794 (2017-12-02)
Alterations in gut hormone signaling are a likely contributing factor to the metabolic disturbances associated with overweight/obesity as they coordinate the timing of feeding behavior, absorption, and utilization of nutrients. These hormones are released in response to food intake, or

関連コンテンツ

MILLIPLEX®マルチプレックス代謝アッセイなどのマルチプレックス・イムノアッセイは、メタボリックシンドローム研究に重要です。糖尿病や肥満など、関連するさまざまな病態の全体像を把握でき、時間とサンプル量を節約できるためです。

質問

レビュー

評価値なし

アクティブなフィルタ

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)